TONG REN TANG (01666) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 3.739 billion, representing a year-on-year decrease of 7.69%. Net profit attributable to company owners was RMB 339 million, down 21.01% compared to the same period last year. Basic earnings per share stood at RMB 0.26.

According to the announcement, the decrease in sales revenue and net profit was primarily due to deepening marketing reforms, accelerated market inventory turnover, and optimization of inventory structure. Market order is gradually improving, and with the advancement of reforms, operational quality will steadily enhance, laying a solid foundation for sustained high-quality development.

During the reporting period, the group had 4 products with sales exceeding RMB 100 million, 28 products with sales between RMB 10 million and RMB 100 million, and 10 products with sales between RMB 5 million and RMB 10 million.

Among the leading products, Liuwei Dihuang Pill series achieved sales revenue growth of approximately 47.99% compared to the same period last year, Jingui Shenqi series grew by approximately 19.55%, and Jingzhi Niuhuang Jiedu Tablet series increased by approximately 4.03%. However, sales revenue for Ganmao Qingre Granule series and Shengmai Drink Oral Liquid series declined compared to the same period last year.

Benefiting from the "major product strategy," products including Zhuanyao Jianshen Pill series, Zhibai Dihuang Pill series, and Guishao Dihuang Pill series all achieved double-digit growth in sales revenue compared to the same period last year.